Evidence map›Paper›PMID 38191418›Full record

ArticleJournal of experimental & clinical cancer research : CR2024

Natural killer cells drive 4-1BBL positive uveal melanoma towards EMT and metastatic disease.

Shi Yong Neo, Mariana M S Oliveira, Le Tong, Yi Chen, Ziqing Chen, Sonia Cismas, Nutsa Burduli, Anna Malmerfelt, Joey Kay Hui Teo, Kong-Peng Lam and 5 more

Open access · goldAbstract read
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
5.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 3 countries.

Shi Yong NeoSingapore Immunology Network (SIgN), Agency for Science, Technology and Research (A*STAR), Singapore, Republic of Singapore.
Mariana M S OliveiraDepartment of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.
Le TongDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Yi ChenDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Ziqing ChenDepartment of Molecular Biology, Lewis Thomas Laboratory, Princeton University, Princeton, NJ, USA.
Sonia CismasDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Nutsa BurduliDepartment of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden.
Anna MalmerfeltDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Joey Kay Hui TeoSingapore Immunology Network (SIgN), Agency for Science, Technology and Research (A*STAR), Singapore, Republic of Singapore.
Kong-Peng LamSingapore Immunology Network (SIgN), Agency for Science, Technology and Research (A*STAR), Singapore, Republic of Singapore.
Evren AliciDepartment of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden.
Leonard GirnitaDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Arnika K WagnerDepartment of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden.
Lisa S WesterbergDepartment of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.
Andreas LundqvistDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden. andreas.lundqvist@ki.se.
Karolinska Institutet · SEAgency for Science, Technology and Research · SGColumbia University Irving Medical Center · USPrinceton University · US

Funding

Barncancerfonden PR2020-0123Cancerfonden 20 0989 PjFCancerfonden 21 1524 PjCancerfonden CAN 2017/1103National Research Foundation Singapore NRF-CRP26-2021RS-0001Radiumhemmets Forskningsfonder 211253Radiumhemmets Forskningsfonder 214083Vetenskapsrådet 2021-01247Vetenskapsrådet 2022-00723
6 · The paper itself

Abstract

backgroundInflammation in the eye is often associated with aggravated ocular diseases such as uveal melanoma (UM). Poor prognosis of UM is generally associated with high potential of metastatic liver dissemination. A strong driver of metastatic dissemination is the activation of the epithelial-mesenchymal transition (EMT) regulating transcription factor ZEB1, and high expression of ZEB1 is associated with aggressiveness of UM. While ZEB1 expression can be also associated with immune tolerance, the underlying drivers of ZEB1 activation remain unclear.

methodsTranscriptomic, in vitro, ex vivo, and in vivo analyses were used to investigate the impact on clinical prognosis of immune infiltration in the ocular tumor microenvironment. A metastatic liver dissemination model of was developed to address the role of natural killer (NK) cells in driving the migration of UM.

resultsIn a pan-cancer TCGA analysis, natural killer (NK) cells were associated with worse overall survival in uveal melanoma and more abundant in high-risk monosomy 3 tumors. Furthermore, uveal melanoma expressed high levels of the tumor necrosis factor superfamily member 4-1BB ligand, particularly in tumors with monosomy 3 and BAP1 mutations. Tumors expressing 4-1BB ligand induced CD73 expression on NK cells accompanied with the ability to promote tumor dissemination. Through ligation of 4-1BB, NK cells induced the expression of the ZEB1 transcription factor, leading to the formation of liver metastasis of uveal melanoma.

conclusionsTaken together, the present study demonstrates a role of NK cells in the aggravation of uveal melanoma towards metastatic disease.

Indexed as

4-1BB LigandMelanomaEpithelial-Mesenchymal TransitionHumansKiller Cells, NaturalMonosomyTumor MicroenvironmentUveal MelanomaUveal Neoplasms4-1BB LigandEpithelial-to-mesenchymal transitionNatural killer cellsUveal melanoma

Identifiers

PMID38191418
PMCPMC10775428
OpenAlexW4390734475

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.